{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:53:35Z","timestamp":1785372815228,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06131-y","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T06:11:08Z","timestamp":1741155068000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial carcinoma in Germany: retrospective CONVINCE study"],"prefix":"10.1007","volume":"151","author":[{"given":"Katrin","family":"Schlack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Machtens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ruhnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Eisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Osowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Guenther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mairead","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Lipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"6131_CR1","unstructured":"Astellas (2023) Padcev (enfortumab vedotin-ejfv). Prescribing information (US)."},{"key":"6131_CR2","unstructured":"Astellas (2024a) Padcev (enfortumab vedotin). Summary of product characteristics (European Medicines Agency)."},{"key":"6131_CR3","unstructured":"Astellas (2024b) European Commission approves Astellas\u2019 PADCEVTM (enfortumab vedotin) in combination with KEYTRUDA\u00ae (pembrolizumab) for first-line treatment of advanced urothelial cancer. https:\/\/www.astellas.com\/en\/news\/29371. Accessed 3 September 2024."},{"key":"6131_CR4","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/oncolo\/oyad174","volume":"28","author":"MA Bilen","year":"2023","unstructured":"Bilen MA, Robinson SB, Schroeder A, Peng J, Kim R, Liu FX, Bhanegaonkar A (2023) Clinical and economic outcomes in patients with metastatic urothelial carcinoma receiving first-line systemic treatment (the IMPACT UC I Study). Oncologist 28:790\u2013798. https:\/\/doi.org\/10.1093\/oncolo\/oyad174","journal-title":"Oncologist"},{"key":"6131_CR5","unstructured":"Bristol Myers Squibb (2024a) Opdivo (nivolumab). Prescribing information (US)."},{"key":"6131_CR6","unstructured":"Bristol Myers Squibb (2024b) Opdivo (nivolumab). Summary of product characteristics (European Medicines Agency)."},{"key":"6131_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2307\/2530286","volume":"38","author":"R Brookmeyer","year":"1982","unstructured":"Brookmeyer R, Crowley J (1982) A confidence interval for the median survival time. Biometrics 38:29\u201341","journal-title":"Biometrics"},{"key":"6131_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","volume":"81","author":"R Cathomas","year":"2022","unstructured":"Cathomas R, Lorch A, Bruins HM, Comp\u00e9rat EM, Cowan NC, Efstathiou JA, Fietkau R, Gakis G, Hern\u00e1ndez V, Espin\u00f3s EL, Neuzillet Y, Ribal MJ, Rouanna M, Thalmann GN, van der Heijden AG, Vestkim\u00e4e E, Witjes JA, Milowsky MI, EAU Muscle-invasive, Metastatic Bladder Cancer Guidelines Panel (2022) The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma. Eur Urol. 81:95\u2013103. https:\/\/doi.org\/10.1016\/j.eururo.2021.09.026","journal-title":"Eur Urol."},{"key":"6131_CR10","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","volume":"395","author":"MD Galsky","year":"2020","unstructured":"Galsky MD, Arija J\u00c1A, Bamias A, Davis ID, De Santis M, Kikuchi E, Garcia-Del-Muro X, De Giorgi U, Mencinger M, Izumi K, Panni S, Gumus M, \u00d6zg\u00fcro\u011flu M, Kalebasty AR, Park SH, Alekseev B, Schutz FA, Li JR, Ye D, Vogelzang NJ, Bernhard S, Tayama D, Mariathasan S, Mecke A, Th\u00e5str\u00f6m A, Grande E, IMvigor130 Study Group (2020) Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 395:1547\u20131557. https:\/\/doi.org\/10.1016\/S0140-6736(20)30230-0","journal-title":"Lancet"},{"key":"6131_CR11","unstructured":"German Guideline Program in Oncology. S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms S3-Leitlinie Harnblasenkarzinom\u2014Version 2.01 (2019). https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/harnblasenkarzinom. Accessed 3 September 2024."},{"key":"6131_CR12","doi-asserted-by":"publisher","first-page":"195.e191","DOI":"10.1016\/j.urolonc.2021.11.014","volume":"40","author":"DM Geynisman","year":"2022","unstructured":"Geynisman DM, Broughton E, Hao Y, Zhang Y, Le T, Huo S (2022) Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States. Urol Oncol 40:195.e191-195.e11. https:\/\/doi.org\/10.1016\/j.urolonc.2021.11.014","journal-title":"Urol Oncol"},{"key":"6131_CR13","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.2217\/fon-2023-0298","volume":"20","author":"M Kearney","year":"2023","unstructured":"Kearney M, Zhang L, Hubscher E, Musat M, Harricharan S, Wilke T (2023) Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis. Future Oncol 20:1123\u20131137. https:\/\/doi.org\/10.2217\/fon-2023-0298","journal-title":"Future Oncol"},{"key":"6131_CR14","doi-asserted-by":"publisher","first-page":"451.e11","DOI":"10.1016\/j.urolonc.2024.07.010","volume":"42","author":"SH Mahmoudpour","year":"2024","unstructured":"Mahmoudpour SH, Knott C, Kearney M, Russo L, Verpillat P (2024) Factors associated with receipt of systemic anticancer treatment for locally advanced or metastatic urothelial carcinoma in England: a population-based study. Urol Oncol  42:451.e11-451.e18. https:\/\/doi.org\/10.1016\/j.urolonc.2024.07.010","journal-title":"Urol Oncol"},{"key":"6131_CR15","doi-asserted-by":"publisher","first-page":"5475","DOI":"10.1007\/s12325-023-02694-9","volume":"40","author":"A Mar\u00e1z","year":"2023","unstructured":"Mar\u00e1z A, Nagy B, Macher T, Jesk\u00f3 J, Tischler E, Csongvai C, Kearney M (2023) Nationwide study of real-world treatment patterns and clinical outcomes in patients with metastatic urothelial carcinoma in Hungary. Adv Ther 40:5475\u20135488. https:\/\/doi.org\/10.1007\/s12325-023-02694-9","journal-title":"Adv Ther"},{"key":"6131_CR16","unstructured":"Merck (2021) European Commission approves BAVENCIO\u00ae (avelumab) for first-line maintenance treatment of locally advanced or metastatic urothelial carcinoma. https:\/\/www.merckgroup.com\/en\/news\/bavencio-1l-uc-eu-approval-25-01-2021.html. Accessed 3 September 2024."},{"key":"6131_CR17","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/j.clgc.2023.09.010","volume":"22","author":"N Milloy","year":"2024","unstructured":"Milloy N, Kirker M, Unsworth M, Montgomery R, Kluth C, Kearney M, Chang J (2024) Real-world analysis of treatment patterns and platinum-based treatment eligibility of patients with metastatic urothelial cancer in 5 European countries. Clin Genitourin Cancer 22:e136-147.e131. https:\/\/doi.org\/10.1016\/j.clgc.2023.09.010","journal-title":"Clin Genitourin Cancer"},{"key":"6131_CR18","doi-asserted-by":"publisher","first-page":"357.e11","DOI":"10.1016\/j.urolonc.2023.03.012","volume":"41","author":"AK Morgans","year":"2023","unstructured":"Morgans AK, Galsky MD, Wright P, Hepp Z, Chang N, Willmon CL, Sesterhenn S, Liu Y, Sonpavde GP (2023) Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced\/metastatic urothelial carcinoma by cisplatin-eligibility. Urol Oncol 41:357.e11-357.e21. https:\/\/doi.org\/10.1016\/j.urolonc.2023.03.012","journal-title":"Urol Oncol"},{"key":"6131_CR9","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Bladder cancer. V4.2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf. Accessed 3 September 2024."},{"key":"6131_CR19","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.7150\/jca.23162","volume":"9","author":"G Niegisch","year":"2018","unstructured":"Niegisch G, Gerullis H, Lin SW, Pavlova J, Gondos A, Rudolph A, Haas G, Hennies N, Kramer MW (2018) A real-world data study to evaluate treatment patterns, clinical characteristics and survival outcomes for first- and second-line treatment in locally advanced and metastatic urothelial cancer patients in Germany. J Cancer 9:1337\u20131348. https:\/\/doi.org\/10.7150\/jca.23162","journal-title":"J Cancer"},{"key":"6131_CR20","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.2217\/fon-2023-1065","volume":"20","author":"G Niegisch","year":"2024","unstructured":"Niegisch G, Grimm MO, Hardtstock F, Krieger J, Starry A, Osowski U, Guenther S, Deiters B, Maywald U, Wilke T, Kearney M (2024a) Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis. Future Oncol 20:1351\u20131366. https:\/\/doi.org\/10.2217\/fon-2023-1065","journal-title":"Future Oncol"},{"key":"6131_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/13696998.2024.2331893","volume":"27","author":"G Niegisch","year":"2024","unstructured":"Niegisch G, Grimm MO, Hardtstock F, Krieger J, Starry A, Osowski U, Guenther S, Deiters B, Maywald U, Wilke T, Kearney M (2024b) Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data. J Med Econ 27:531\u2013542. https:\/\/doi.org\/10.1080\/13696998.2024.2331893","journal-title":"J Med Econ"},{"key":"6131_CR22","doi-asserted-by":"crossref","unstructured":"Niegisch G, Kearney M, Krieger J, Osowski U, Deiters B, Maywald U, Wilke T, Grimm MO (2024c). Insights into second-line systemic treatment selection in patients with metastatic urothelial carcinoma: results of a retrospective observational study in Germany. Ann Oncol. 35(suppl 2):Abstract 1995P.","DOI":"10.1016\/j.annonc.2024.08.2081"},{"key":"6131_CR23","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles T, Cs\u0151szi T, \u00d6zg\u00fcro\u011flu M, Matsubara N, G\u00e9czi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fl\u00e9chon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A, KEYNOTE-361 Investigators (2021) Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 22:931\u2013945. https:\/\/doi.org\/10.1016\/S1470-2045(21)00152-2","journal-title":"Lancet Oncol"},{"key":"6131_CR24","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, Shariat SF, Szabados B, van der Heijden MS, Gillessen S, ESMO Study Guidelines Committee (2022) Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 33:244\u2013258. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.012","journal-title":"Ann Oncol."},{"key":"6131_CR25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, Shariat SF, Szabados B, van der Heijden MS, Gillessen S, ESMO Study Guidelines Committee (2024a) ESMO clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol 35:485\u2013490. https:\/\/doi.org\/10.1016\/j.annonc.2024.03.001","journal-title":"Ann Oncol"},{"key":"6131_CR26","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, G\u00fcm\u00fc\u015f M, Mar N, Loriot Y, Fl\u00e9chon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS (2024b) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390:875\u2013888. https:\/\/doi.org\/10.1056\/NEJMoa2312117","journal-title":"N Engl J Med"},{"issue":"6 suppl","key":"6131_CR27","doi-asserted-by":"publisher","first-page":"Abstract 463","DOI":"10.1200\/JCO.2023.41.6_suppl.463","volume":"41","author":"J Puente","year":"2023","unstructured":"Puente J, Pinto A, Mendez Vidal MJ, Garcia del Muro X, Maroto-Rey P, Vazquez-Estevez S, Luque R, Anido U, Strunz-McKendry T, Upadhyay A, Montes J, Ortiz Nu\u00f1ez A, Gonz\u00e1lez Portela J, Castellano D (2023) Real-world treatment patterns, survival outcomes, and health care resource utilization (HCRU) for locally advanced or metastatic urothelial carcinoma (la\/mUC) in Spain. J Clin Oncol  41(Suppl 6):Abstract 463. https:\/\/doi.org\/10.1200\/JCO.2023.41.6_suppl.463","journal-title":"J Clin Oncol"},{"key":"6131_CR28","unstructured":"Robert Koch Institut (2024) Cancer in Germany 2019\/2020. https:\/\/www.krebsdaten.de\/Krebs\/EN\/Content\/Publications\/Cancer_in_Germany\/cancer_in_germany.html. Accessed 21 January 2025."},{"key":"6131_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/medsci8010015","volume":"8","author":"K Saginala","year":"2020","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A (2020) Epidemiology of bladder cancer. Med Sci (Basel) 8:15. https:\/\/doi.org\/10.3390\/medsci8010015","journal-title":"Med Sci (Basel)"},{"issue":"suppl 2","key":"6131_CR30","doi-asserted-by":"publisher","first-page":"Abstract 2388P","DOI":"10.1016\/annonc\/annonc1310","volume":"34","author":"K Schlack","year":"2023","unstructured":"Schlack K, Kubin T, Ruhnke M, Schulte C, Machtens S, Eisen A, Osowski U, Guenther S, Kearney M, Lipp R, Schmitz S (2023) Split-dose cisplatin plus gemcitabine use and associated clinical outcomes in the first-line (1L) treatment of locally advanced or metastatic urothelial cancer (la\/mUC): results of a retrospective observational study in Germany (CONVINCE). Ann Oncol 34(Suppl 2):2388. https:\/\/doi.org\/10.1016\/annonc\/annonc1310","journal-title":"Ann Oncol"},{"key":"6131_CR31","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pds.1357","volume":"16","author":"S Suissa","year":"2007","unstructured":"Suissa S (2007) Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 16:241\u2013249. https:\/\/doi.org\/10.1002\/pds.1357","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"suppl 2","key":"6131_CR32","first-page":"Abstract EE831","volume":"27","author":"A Tricotel","year":"2024","unstructured":"Tricotel A, Casarotto E, Minacori R, Strunz-McKendry T, Karzazi K, Leyland K, Vuillet M, Thomas MC, Joly F, Roupr\u00eat M, Culine S (2024) Treatment patterns, healthcare resource utilization, and costs of patients with locally advanced and metastatic urothelial cancer in France: a non-interventional database study. Value Health. 27(suppl 2):831","journal-title":"Value Health."},{"key":"6131_CR33","unstructured":"US Department of Health and Human Services (2017) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed 3 September 2024."},{"key":"6131_CR34","unstructured":"US Food and Drug Administration (2023) FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer. Accessed 3 September 2024."},{"key":"6131_CR35","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J, Oldenburg J, Chatta G, \u00dcr\u00fcn Y, Ye D, He Z, Valderrama BP, Ku JH, Tomita Y, Filian J, Wang L, Purcea D, Patel MY, Nasroulah F, Galsky MD (2023) Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med 389:1778\u20131789. https:\/\/doi.org\/10.1056\/NEJMoa2309863","journal-title":"N Engl J Med"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06131-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06131-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06131-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T14:25:24Z","timestamp":1744640724000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06131-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["6131"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06131-y","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"16 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.S. has served in speakers bureaus and consulting or advisory roles for AAA, Amgen, Apogepha, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb (personal and institutional), Eisai, EUSA-Pharma, Fosanis, Ipsen, Janssen Cilag, Merck, MSD, Novartis (personal and institutional), Pfizer (personal and institutional), and Roche, and has received travel, accommodations, and expenses from Astellas, AstraZeneca, Bayer, Janssen Cilag, Ipsen, Merck, and Sanofi-Aventis. S.M. has served in consulting or advisory roles for Amgen, AstraZeneca, Bayer, BD, Bebig, Janssen-Cilag, MSD, Pfizer, and Sanofi-Aventis, and has participated in speakers bureaus for Amgen, Apogepha, Astellas, AstraZeneca, Bayer, BD, Bebig, Ipsen, Janssen-Cilag, Merck, MSD, Novartis, Pfizer, Sanofi-Aventis, and Takeda. T.K. has served in speakers bureaus and consulting or advisory roles for AstraZeneca, BMS, Boehringer-Ingelheim, GSK, Janssen, MSD, Roche, and Takeda. M.R., C.S., and A.E. have nothing to disclose. U.O. reports employment with Merck Healthcare Germany GmbH, Weiterstadt, Germany, an affiliate of Merck KGaA. S.G. reports employment with Merck Healthcare KGaA, Darmstadt, Germany when the study was conducted. M.K. reports employment with Merck Healthcare KGaA, Darmstadt, Germany and reports stock and other ownership interests with Merck, Novartis, and UCB. R.L. has served in consulting or advisory roles for AstraZeneca, Gilead, Janssen-Cilag, Merck, Omnicare, Sanofi, and Takeda; has served in a speakers bureau for Merck; and has provided project support for AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead, Janssen-Cilag, Merck, and Pfizer. S.S. has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was submitted to the independent ethical committee of the Chamber of Physicians in Northern Rhine, which confirmed that because data were fully anonymized, patient informed consent was not required. The protocol was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"100"}}